Stocktoria
Wave Life Sciences Ltd. WVE
Wave Life Sciences Ltd. (WVE) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $42.7M at a -478.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.814 |
| Retained earnings / assets | -2.077 |
| EBIT / assets | -0.337 |
| Equity / liabilities | 4.617 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| WVE | Wave Life Sciences Ltd. | 2/9 | 1.15 | — | -60.5% |
| BFRI | Biofrontera Inc. | 1/9 | -15.24 | — | +11.7% |
| XLO | Xilio Therapeutics, Inc. | 4/9 | -6.58 | — | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | 4/9 | -0.86 | — | +17.6% |
| AQST | Aquestive Therapeutics, Inc. | 2/9 | -8.08 | — | -22.6% |
| SEPN | Septerna, Inc. | 4/9 | 3.75 | — | — |
| PTGX | Protagonist Therapeutics, Inc | 4/9 | 13.41 | — | -89.4% |
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
FAQ
Is WVE financially healthy?
Wave Life Sciences Ltd.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does WVE pay a dividend?
No, Wave Life Sciences Ltd. does not currently pay a dividend.
How profitable is WVE?
In FY2025, Wave Life Sciences Ltd. had a net margin of -478.3% and a return on equity of -39.4%.
What is the analyst price target for WVE?
The average Wall-Street price target for Wave Life Sciences Ltd. is $21.94, about 318.7% above the recent price, from 16 analysts.
Is WVE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Wave Life Sciences Ltd.: a Piotroski F-score of 2/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.